Identification of seven loci affecting mean telomere length and their association with disease by Codd, Veryan et al.
Identification of seven loci affecting mean telomere length and
their association with disease
A full list of authors and affiliations appears at the end of the article.
Abstract
Inter-individual variation in mean leukocyte telomere length (LTL) is associated with cancer and
several age-associated diseases. Here, in a genome-wide meta-analysis of 37,684 individuals with
replication of selected variants in a further 10,739 individuals, we identified seven loci, including
five novel loci, associated with mean LTL (P<5x10−8). Five of the loci contain genes (TERC,
TERT, NAF1, OBFC1, RTEL1) that are known to be involved in telomere biology. Lead SNPs at
two loci (TERC and TERT) associate with several cancers and other diseases, including idiopathic
pulmonary fibrosis. Moreover, a genetic risk score analysis combining lead variants at all seven
loci in 22,233 coronary artery disease cases and 64,762 controls showed an association of the
alleles associated with shorter LTL with increased risk of CAD (21% (95% CI: 5–35%) per
standard deviation in LTL, p=0.014). Our findings support a causal role of telomere length
variation in some age-related diseases.
Telomeres are the protein bound DNA repeat structures at the ends of chromosomes, which
have an important role in maintaining genomic stability1. Furthermore, they play a critical
role in regulating cellular replicative capacity2. During somatic cell replication, telomere
length (TL) progressively shortens due to the inability of DNA polymerase to fully replicate
the 3’ end of the DNA strand. Once a critically short TL is reached, the cell is triggered to
enter replicative senescence and subsequently cell death1, 2. Conversely, in germ cells and
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other stem cells requiring renewal, TL is maintained by the enzyme telomerase, a
ribonucleoprotein which contains the RNA template TERC and a reverse transcriptase
TERT3. Both longer and shorter TL are associated with increased risk of certain cancers4, 5,
and reactivation of telomerase, which by-passes cellular senescence, is a common
requirement for oncogenic progression6. Therefore, TL is an important determinant of
telomere function.
Mean TL shows considerable inter-individual variability and has high heritability with
estimates varying between 44–80%7–9. Most of these studies have measured mean TL in
blood leukocytes. However, there is evidence that within an individual, mean TL of
leukocytes (LTL) and other tissues is highly correlated10, 11. In cross-sectional population
studies mean LTL is longer in women than in men and is inversely associated with age
(declining by between 20–40 base-pairs (bp) per year)9, 12–14. Furthermore, shorter age-and
sex-adjusted mean LTL has been found to be associated with risk of several age-related
diseases, including CAD12–15 and has been advanced as a marker of biological ageing16.
However, the extent to which the association of shorter LTL with age-related disorders is
causal in nature remains unclear. Identifying genetic variants that affect TL and testing their
association with disease could clarify any causal role.
So far, common variants at two loci on Chr3q26 (TERC)17–19 and Chr10q24.33 (OBFC1)18,
that explain <1% of the variance in TL, have shown a replicated association with mean LTL
in genome-wide association (GWA) studies. To identify further genetic determinants of LTL
we conducted a large scale GWA meta-analysis of 37,684 individuals from 15 cohorts,
followed by replication of selected variants in a further 10,739 individuals from 6 additional
cohorts.
Details of the studies included in the GWA meta-analysis and in the replication phase are
given in Supplementary Note and key characteristics summarised in Supplementary Tables
1a and 1b, respectively. All subjects were of European descent, the majority of the cohorts
were population-based and three of the replication cohorts were additional subjects from
studies used in the meta-analysis. The genotyping platforms and the imputation method (to
HapMap 2 build 36) used by each GWA cohort are summarised in Supplementary Table 2.
Mean LTL was measured in each cohort using a quantitative PCR method and is expressed
as a T/S ratio (Online Methods, Supplementary Note).
LTL, adjusted for age, sex, and any study-specific covariates was then analysed for
association with genotype using linear regression within each study and results adjusted for
genomic inflation control factors (Supplementary Table 2). An inverse-variance weighted
meta-analysis for 2,362,330 SNPs (Online Methods) was performed with further correction
for the overall genomic inflation control factor (λ = 1.007). The quantile-quantile plot for
the meta-analysis is shown in Supplementary Figure 1.
SNPs in 7 loci showed association with mean LTL at genome-wide significance (P<5x10−8,
Fig 1, Table 1, Fig 2 and Supplementary Fig 2). The association of the lead SNP on
chromosome 2p16.2 (rs11125529) was very close to the threshold for genome-wide
significance , while the lead SNP in a further locus on 16q23.3 (rs2967374) fell just short of
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this threshold (Table 1). We therefore sought further validation of these two loci. We
confirmed the association of rs11125529 but not of rs2967374 (Table 1). The combined P
value from the GWA meta-analyses and replication cohorts for rs11125529 was 7.50x10−10.
There was no evidence of sex-dependent effects or additional independent signals at any of
these loci (Online Methods, Supplementary Tables 3 and 4).
Details of key genes in each locus associated with LTL and their location in relation to the
lead SNP are given in Supplementary Table 5. The most significantly associated locus we
found was the previously reported TERC locus on 3q26 (Figs 1 and 2, Table 1)17. In
addition to this, four further loci – 5p15.33 (TERT), 4q32.2 (NAF1, nuclear assembly factor
1), 10q24.33 (OBFC1, oligonucleotide/oligosaccharide-binding fold containing 1)18 and
20q13.3 (RTEL1, regulator of telomere elongation helicase 1) - harbour genes that encode
proteins with known function in telomere biology3, 20–23. NAF1 is a protein which is
required for H/ACA box snoRNA assembly, the RNA family to which TERC belongs20.
Therefore, the three most significantly-associated loci (3q26, 5p15.33 and 4q32.2) harbour
genes involved in the formation and activity of telomerase. We therefore examined whether
the lead SNPs at these loci as well as the other identified loci associate with leukocyte
telomerase activity in available data from 208 individuals. We did not find significant
association of any of the variants with telomerase activity (Supplementary Table 6).
However, the study only had 80% power (α of 0.05) to detect a SNP effect that explained
3.7% of the variance in telomerase activity and therefore smaller effects are likely to have
been missed in this exploratory analysis.
We also replicated the previously reported OBFC1 locus18. OBFC1 is a component of the
telomere binding CST complex also containing CTC1, and TEN121. In yeast this complex
binds to the single stranded G overhang at the telomere and functions to promote telomere
replication. RTEL1 is a DNA helicase that has been shown to play important roles in setting
telomere length, telomere maintenance and DNA repair in mice22, 23. However, it should be
noted that the lead SNP lies 94 kb from RTEL1. The remaining two loci (19p21 and 2p16.2)
do not harbour obvious candidate genes related to telomere biology. The locus on 19p12
contains a cluster of genes encoding zinc finger proteins (ZNFs) while that on 2p16.2 spans
both the ACYP2 gene which encodes a muscle specific acylphosphate and TSPYL6, a gene
within intron 3 of ACYP2 that shares homology with nucleosome assembly factors. There is
evidence that ACYP2 is linked to stress induced apoptosis in rat muscle24.
In order to gain better functional insight into the associated loci we undertook various
bioinformatics analyses (Online Methods). Details of the findings are given in the
Supplementary Note and in Supplementary Table 7. SNPs in high LD with the lead SNP
were found to lie within potential regulatory elements of TERC, NAF1 and OBFC1.
However, similar SNPs were also present for other genes in some of the loci. These findings
emphasise that although strong candidate genes are located in some of the loci, at this stage
we cannot overlook the potential involvement of other genes within each region.
Each of the identified loci explains a relatively small proportion of the total variance in LTL
(Table 1). In order to put this in context, we calculated the effect of the lead SNP at each
locus in terms of equivalent age-related shortening of LTL based on an estimate of age-
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related attrition in T/S ratio calculated across all cohorts (Supplementary Fig 3). We saw
per-allele effects using this measure equivalent to between 1.9–3.9 years of age-related
attrition in T/S ratio (Table 1). The qPCR method used here to measure LTL cannot be used
to directly calculate the effect on LTL in base pairs (bp). However, many prior studies that
have used Southern blotting to measure LTL have shown that mean LTL attrition rate is
about ~30 bp per year8, 12–14, 25. This suggests that the per allele effect of the different SNPs
on LTL in base pairs ranges from ~ 57 to 117 bp (Table 1).
As both shorter and longer mean LTL have been linked to increased risk of various diseases,
we searched genetic association databases for disease associations with the LTL associated
SNPs (Supplementary Table 8). The rs10936599 (TERC) allele associated with longer LTL
associates with increased risk of colorectal cancer19 and with two autoimmune diseases,
multiple sclerosis (longer LTL allele) and celiac disease (shorter LTL allele). The lead SNP
for the 5p15.33 (TERT) locus is associated with different cancer types (both shorter and
longer LTL alleles) and with increased risk of idiopathic pulmonary fibrosis (shorter LTL
allele), a disease that has previously been shown to be associated with shorter LTL26.
One of the most widely reported associations for LTL to date has been that between shorter
mean LTL and CAD12–14, 25. Because LTL is also affected by other risk factors for CAD
such as oxidative stress27–29, it has been unclear whether the association of shorter LTL with
CAD is primary or secondary. To investigate whether the association could be causal, we
examined the association of both individual lead SNPs and a genetic risk score (GRS) based
on a combination of all seven SNPs, (adjusted for their effect size) with CAD in the
CARDIoGRAM GWAS meta-analysis comprising 22,233 CAD cases and 64,762 controls
of European descent30, using the approach recently described by the ICBP Consortium31.
Although the results for individuals variants were not significant, 6 out of 7 variants showed
consistency in direction and the combined GRS analysis showed a significant association (p
= 0.014) of the allele associated with shorter LTL with increased risk of CAD (Fig 3).
Shorter mean LTL equivalent to one SD in LTL was associated with a 21% (95% CI 5% –
35%) higher risk of CAD.
Here, we report five novel and confirm two previously reported loci that associate with
mean LTL in humans. A specific motivation for our study is the observation that variation in
LTL is associated with several age-related diseases and the desire to establish whether this
link is causal. This is particularly challenging to disentangle because other environmental
and life-style factors also impact on TL29, 32–34. The most persuasive evidence for a causal
role comes from in vitro and in vivo manipulation of telomerase activity which impacts on
TL and has been shown to enhance or reverse senescence and ageing-associated
phenotypes35–39. Here, we show that some of the genetic variants associated with LTL are
also associated with risk of specific cancers as well as other diseases some of which have
been shown to be previously associated with shorter LTL, suggesting a causal link. An
interesting finding was that alleles associated with both shorter and longer telomeres showed
associations with specific cancers suggesting that variation in LTL in either direction may
contribute to the development of specific cancers.
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As an example of a complex disease that has been shown to be associated with shorter LTL
we examined CAD. Through an analysis of a large GWA database of CAD30, we found that
while individually the lead SNPs at each of the TL-associated loci were not significantly
associated with risk of CAD (probably at least in part reflecting their weak individual effects
on LTL and low power), in a combined analysis, alleles associated with shorter LTL were
associated with a significantly higher risk of CAD. Because the variants at each of the loci
could have other biological effects that could impact on their association with CAD through
LTL (and possibly explain why the NAF1 locus may be trending in the opposite direction),
some caution is required in the interpretation of this association. Nonetheless, the finding is
consistent with that in the prospective WOSCOPS study where, after adjustment for other
CAD risk factors, baseline LTL was associated with a 44% higher risk of CAD over the
ensuing mean 5.5 years of follow-up in individuals in the tertile with the shortest LTL
compared with the longest LTL13. Our finding here therefore supports a causal association
of shorter LTL with CAD and further mechanistic investigation of this relationship is
warranted.
In summary, we provide novel insights into the genetic determination of a structure that is
critically involved in genomic stability and cellular function. Our findings suggest that
variants in several genes encoding proteins with known function in telomere biology as well
as other genes influence LTL. The findings provide a framework for a genetic approach to
investigating the causal role of telomere length in ageing-related diseases.
Online Methods
Subjects
A total of 37,684 individuals from 15 cohorts were used in the GWAS meta-analysis, along
with a further 10,739 individuals from 6 cohorts for replication of selected variants.. All
individuals were of European descent. Full details of the discovery and replication cohorts
are given in the Supplementary Note and key characteristics summarised in Supplementary
Table 1.
Telomere Length Measurements and QC analysis
Mean LTL was measured using a quantitative PCR-based technique40, 41 in all samples.
This method expresses telomere length as a ratio (T/S) of telomere repeat length (T) to copy
number of a single copy gene (S), within each sample. To standardise across plates either a
calibrator sample or a standard curve were used for quantification. LTL measurements were
made in five separate laboratories. Laboratories used are listed for each cohort in
Supplementary Table 1 and specific details for the methods used are given in Supplementary
Note. The majority of the samples (67% of the total) were run in a single laboratory with
mean inter-run coefficients of variation for LTL measurements in individual cohorts ranging
between 2.7% and 3.9%. The remaining samples were run across 4 other laboratories
(Supplementary Note). Mean LTL was first assessed for age-related shortening and for an
association of longer LTL with female sex in all cohorts and showed expected associations
(Supplementary Tables 1a and 1b).Ranges in T/S ratios were found to vary between cohorts
measured in different laboratories (Supplementary Table 1), largely due to differences in the
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calibrator or standard DNA used. We therefore standardised LTL within each cohort using a
Z-transformation approach. The Z-transformation was performed separately for males and
females for sex-stratified analysis. Effects of age, adjusted for sex, on LTL were estimated
in a multiple regression model on untransformed and Z-transformed TL in each study
separately and combined using a random-effects meta-analysis in STATA (version 11.2,
Supplementary Fig 3).
Genotyping, GWAS analysis and study level QC
All discovery cohorts had genome-wide genotype information generated on a standard
genotyping platform and include imputed genotypes based on HapMapII CEU build 36 as a
reference. Detailed information about individual genotyping platforms, imputation methods,
and analysis software is provided in Supplementary Table 2.Within each cohort SNP
associations with LTL were analyzed by linear regression assuming additive effects with
adjustment for age and sex as well as study specific covariates where appropriate, such as
adjustments for family and population structure (Supplementary Table 2). All study-specific
files underwent extensive quality control procedures before meta-analysis. All files were
checked for completeness and plausible descriptive statistics on all variables partly
supported by the gwasqc function in R. Allele frequencies were checked for compliance
with HapMap. In addition to the study-specific quality control filters, we included SNP
results of a study in our meta-analysis only if the SNP imputation quality score was >0.5 and
if the minor allele frequency was >1%. Only SNPs which were available in >50% of the
total sample size over all studies were analyzed, resulting in a total number of 2,362,330
SNPs in the meta-analysis.
Meta-analyses
Meta-analysis of all individual study associations was conducted using inverse variance
weighting in Stata. As a measure for between study heterogeneity I2 was calculated42. For
SNPs with I2≤40% fixed-effects models were applied and random-effects were applied for
SNPs with I2>40%. Fixed-effects results were verified by an independent analyst using
METAL43. Before meta-analysis, standard errors of each study were genomic control
corrected using study specific lambda estimates as provided in Supplementary Table 2. The
overall inflation factor lambda of the meta-analyzed results was 1.007. Results were further
corrected for this. SNPs showing association with telomere length with P-values below
5x10−8, which corresponds to a Bonferroni correction of one million independent tests, were
considered to be statistically significant44.
Replication study
Replication was sought for two SNPs reaching borderline significant p-values in the
discovery analysis. Further subsets of NTR and ECGUT along with the Leiden 85-plus
study had LTL measurements performed. LTL measurements were available for the
GRAPHIC, PLIC cohorts and for additional samples of PREVEND. De-novo genotyping
was performed either using a commercial genotyping service (GRAPHIC, PREVEND,
KBioscience, UK) or by Taqman genotyping as described previously45. In these studies, the
same model was applied as in the discovery studies. Single study results were meta-analyzed
using inverse-variance weighted fixed-effects models in STATA
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Genome-wide associations were additionally conducted separately in women and men in
order to investigate whether sex-specific signals existed. Furthermore, all top SNPs from the
overall discovery GWAS, were tested for differences between women and men by means of
the normally distributed test-statistic (betaw-betam)/sqrt(sew2+sem2). The results of this
analysis are given in Supplementary Table 3.
Conditional association analysis
Regional association plots were generated using LocusZoom46 for each of the loci
containing significantly associated SNPs. These were assessed to check that further SNPs in
high linkage disequilibrium (LD) with the lead SNP also showed some degree of association
with TL. This was confirmed; however it was evident that some regions (5p15.33, 10q24.33
and 20q13.3) contained SNPs in low LD with the lead SNP that also showed association to
LTL. In order to assess whether independent signals existed at these loci conditional
analyses were carried out. Within a subset of studies, a multiple regression model was
calculated for each locus including both SNPs. Adjustments were made in the same way as
in the single SNP models. Individual study results were meta-analyzed using fixed-effects in
R and compared to the meta-analysis results of single SNP models within the same subset of
studies. Independency was defined as the percentage-change in the effect estimate between
the single and the multiple SNP model being ≤25%. The data is given in Supplementary
Table 4.
Calculations of explained variances
Explained variances were calculated based on the effect estimates (beta) and allele
frequencies (EAF) of each single SNP by 2*EAF*(1-EAF)*(beta2/var) as suggested
before47. The phenotypic variance (var) is equal to 1 as the analysis was performed using Z-
transformed telomere length.
Genetic risk scores
In order to assess the impact of these variants on risk of CAD we performed a multiple SNP
risk score analysis as previously described31. This method is equivalent to a fixed-effects
inverse-variance weighted meta-analysis of the ratio between the two traits. Lookups were
performed in CARDIoGRAM30 [β1] to obtain the effect sizes for the seven SNPs along with
the standard errors for CAD risk. These were then converted to a ratio[β3] along with its
standard error using the estimates from the telomere meta-analysis[β2]. We removed the
BHF-FHS and NBS data from this analysis because they were included in the
CARDIoGRAM analysis and to avoid the possibility of reverse causation given the nature of
the BHF-FHS sample. The single SNP results were then meta-analysed using fixed-effects
with inverse-variance weighting. The pooled estimate can be interpreted as the effect of a
standard deviation increase in telomere length on the risk of CAD.
Leukocyte telomerase activity assays
Details of the cohort are given in Supplementary Note. Peripheral blood mononuclear cells
(PBMCs) were freshly isolated from whole blood by Ficoll-Pague Premium (Sigma-Aldrich,
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St. Louis, MO) gradient centrifugation within 1 hour after blood draw. Isolated PBMCs
were stored in a cryopreservation media composed of RPMI-1640, 10% dimethyl sulfoxide
and 10% fetal bovine serum at liquid nitrogen tank until further processing. Telomerase
activity was assayed by the Telo TAGGG Telomerase PCR ELISA kit (Roche Applied
Science, Indianapolis, IN) (TRAP assay) as per the manufacturers’ protocol using 2x10−5
cells/assay. An extract from 2000 cells were used for TRAP reactions. Sample telomerase
activity was expressed as ratio of telomerase activity value divided by control HK293
telomerase activity value from 1000 cells. Intra-assay CV was5.9% and inter-assay CV is
4.8%. Telomerase activity was log transformed to obtain better approximations of the
normal distribution prior to analysis. Association analyses with genotype were performed
using regression and an additive model with adjustment for age, sex and ethnicity. The
interaction between SNP and ethnicity was also built in the regression model to test whether
the effect of the SNP on telomerase activity is ethnicity dependent. The power of the study
to detect a SNP effect on telomerase activity was computed using the Genetic Power
Calculator48.
Bioinformatics analyses
For all analyses we tested lead SNPs and SNPs with an r2>0.7 to the lead SNP identified
through the 1000 Genomes study at each. Functional predictions of any identified coding
variants were carried out using PolyPhen249 and SIFT50. In order to assess whether any
variants influenced gene expression we searched two available genome-wide gene
expression databases, the monocyte genome-wide gene expression data from the Gutenburg
Heart Study51 and the Genotype-Tissue Expression Project (GTEx) data base, which
includes liver, brain and lymphoblastoid cell types. To identify regulatory variants we
searched ENCODE data in the UCSC Genome Browser database52. to examine whether any
SNPs were located within promoter, enhancer or insulator regions (Chromatin State
Segmentation), methylation sites (predicted CpG islands and methylation status of the CpG
site using data from the Methyl 450K Bead array data and Bisufite sequencing), conserved
elements, conserved transcription factor binding sites and regions of known transcription
factor binding as shown by transcription factor ChIP-seq.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Signal intensity plot of genotype association with telomere length
Data is displayed as –log10P values against chromosomal location for the 2,362,330SNPs that were tested. The dotted line
represents a genome-wide level of significance at P=5x10−8. The 7 loci that showed an association at this level are plotted in
red.
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Figure 2. Regional associations plots for the associated loci
For each SNP –log10P is plotted against base pair position for each of the loci (A-G). Regional plots are shown in order of
strongest association - Chr3q26 (A), Chr5p15.33 (B), Chr4q32.2 (C), Chr10q24.33 (D), Chr19p12 (E) Chr20q13.3 (F),
Chr2p16.2 (G). Within each locus the lead SNP is represented in purple and the LD relationship of other SNPs to this is
indicated by the colour as shown in the right hand panel of each plot. Blue peaks represent recombination rates (HapMap 2) and
the RefSeq genes within each region are given in the lower panel.
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Figure 3. TL variants and risk of CAD
Forest plot showing the effect of telomere length on CAD risk obtained for each SNP using a risk score analysis31 for each SNP.
Effect sizes are plotted with 95% CI intervals. The overall estimate is from a fixed-effects meta-analysis over all SNPs, where
the odds ratio relates to the change in CAD risk for a standard deviation change in telomere length.
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